Alvotech and Stada have celebrated their debut launch of biosimilar competition to Stelara (ustekinumab) in Europe, with the introduction of the firms’ partnered Uzpruvo version “across a majority of European countries.”
While the specific launch markets were not disclosed, the firms said the initial roll-out covered “the largest markets in the region, where pricing and reimbursement approvals have been secured for market entry.” And launches in further European countries “are scheduled over the coming months, following national price approvals, via a fully European supply chain” that includes manufacturing at Alvotech’s facility in Reykjavik, Iceland.
Uzpruvo is indicated for Crohn’s disease and psoriatic arthritis in adults, as well as plaque psoriasis in adults and children aged from six years. However, Stada and Alvotech acknowledged, “Uzpruvo is currently not approved for the ulcerative colitis indication, since the originator still has exclusivity for this indication.”
The launch “comes immediately upon expiry of exclusivity rights for the molecule used to treat certain conditions in gastroenterology, dermatology and rheumatology,” the companies noted, in line with previous indications that Uzpruvo would be introduced as soon as possible following the July expiry of a European supplementary protection certificate covering the biologic brand (see sidebar).
Stada And Alvotech Eye Launch Date For Ustekinumab After EU Approval
This came after Alvotech struck a series of settlement agreements with originator Johnson & Johnson to pave the way for launching ustekinumab in major global markets. (Also see "Alvotech Clears A Path For 2024 Ustekinumab In Major Global Markets" - Generics Bulletin, 15 February, 2024.)
Stada and Alvotech said the launch “creates competition at the earliest opportunity, enabling straightforward switching to broaden patient access and control costs in a growing market,” with “accessible indications currently estimated at approximately €2.4bn ($2.6bn)” according to the firms.
The launch follows Alvotech and Stada’s partnered launch of the Hukyndra (adalimumab) 100mg/ml biosimilar to Humira in 2022. (Also see "Stada And Alvotech Launch Higher-Strength Adalimumab In Europe" - Generics Bulletin, 9 June, 2022.)
“Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” highlighted Stada CEO Peter Goldschmidt, emphasizing the “opportunity to improve patient access through wider usage of a life-changing biological treatment.”
And Alvotech CEO Robert Wessman said the company was “delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adding that the launch “symbolizes the robustness of our platform, the value of our partnership with Stada, and our collective focus on the importance of biosimilars.”
Stada also pointed to the unique features of its version of ustekinumab, with Uzpruvo “offered in a pre-filled syringe format featuring a thinner needle than the reference product” as well as being “latex-free to minimize the risk of allergic reactions.”
With the latest launch, Alvotech has now launched its Stelara biosimilar via partners in Europe, Canada and Japan. (Also see "Alvotech And Jamp Launch First Stelara Biosimilar In Canada" - Generics Bulletin, 4 March, 2024.) (Also see "Alvotech’s Japanese Ustekinumab Nod Is ‘First For Global Markets’" - Generics Bulletin, 26 September, 2023.)
Two Other Biosimilars Approved In Europe
While Stada and Alvotech’s Uzpruvo has claimed the first European launch, other ustekinumab biosimilars are waiting in the wings.
Generics Bulletin Explains: After Humira Biosimilars, Will It Be Groundhog Day For Stelara?
Samsung Bioepis and Sandoz’s partnered Pyzchiva version was approved in April. (Also see "Sandoz And Samsung Celebrate Stelara Rival’s EU Approval" - Generics Bulletin, 23 April, 2024.) However, commercialization company Sandoz has so far not indicated specific launch details and declined to comment on its plans in the wake of Stada and Alvotech’s European launch.
Similarly, Amgen has also received approval for its Wezenla version that was endorsed by the European Medicines Agency earlier this year, but also has not made public its launch plans for the product. (Also see "…And Amgen Makes Three: Another Ustekinumab Biosimilar Gets Go-Ahead In EU" - Generics Bulletin, 26 April, 2024.)
Further to these two ustekinumab rivals, Celltrion’s Steqeyma biosimilar rival to Stelara was also recently granted a positive opinion from the EMA’s Committee for Medicinal Products for Human Use. However, this has yet to be converted into a formal marketing authorization by the European Commission. (Also see "More Stelara Biosimilars Line Up For Launch In US And EU" - Generics Bulletin, 1 July, 2024.)
